中文名称: | Sofiniclin | ||||
---|---|---|---|---|---|
英文名称: | Sofiniclin | ||||
别名: | Sofiniclin ABT894 | ||||
CAS No: | 799279-80-4 | 分子式: | C10H11Cl2N3 | 分子量: | 244.12 |
CAS No: | 799279-80-4 | ||||
分子式: | C10H11Cl2N3 | ||||
分子量: | 244.12 |
基本信息
产品编号: |
S10967 |
||||
产品名称: |
Sofiniclin |
||||
CAS: |
799279-80-4 |
储存条件 |
粉末 |
-20℃ |
四年 |
|
|
||||
分子式: |
溶于液体 |
-80℃ |
6个月 |
||
分子量: |
244.12 |
-20℃ |
1个月 |
||
化学名: |
(1s,5s)-3-(5,6-dichloropyridin-3-yl)-3,6-diazabicyclo[3.2.0]heptane |
||||
Solubility (25°C): |
|||||
体外:
|
DMSO |
|
|||
Ethanol |
|
||||
Water |
|
||||
体内(现配现用): |
|
||||
<1mg/ml表示微溶或不溶。 |
|||||
普西唐提供的所有化合物浓度为内部测试所得,实际溶液度可能与公布值有所偏差,属于正常的批间细微差异现象。 |
|||||
请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液;⼀旦配成溶液,请分装保存,避免反复冻融造成的产品失效。 |
制备储备液
浓度
溶液体积 质量 |
1mg |
5mg |
10mg |
1mM |
4.0963mL |
20.4817mL |
40.9635mL |
5mM |
0.8193mL |
4.0963mL |
8.1927mL |
10mM |
0.4096mL |
2.0482mL |
4.0963mL |
生物活性
产品描述 |
一种nAChR的激动剂,作为注意力缺陷症的潜在的非刺激性研究。 |
靶点 |
nAChR |
体外研究 |
Sofiniclin is more potent than ABT-089 at both receptor subtypes,with Ki values of 1.9nM for 125I-α-conotoxinMII binding and of 1.3nM for 125I-epibatidine binding. |
体内研究 |
Sofiniclin (0.001 to 0.10mg/kg,p.o.) produces significant reductions in LIDs compared to vehicle monkey.Sofiniclin (0.1mg/kg) does not decrease LIDs in monkeys with severe nigrostriatal damage. |
推荐实验方法(仅供参考)
激酶实验: |
Receptor studies with ABT-089 and Sofiniclin are done using rat striatal sections.α6β2* nAChR levels are assayed using 125Iα-conotoxinMII (α-CtxMII) (specific activity,2200 Ci/mmol).α4β2* nAChRs are measured by determining the binding of 125Iepibatidine (specific activity,2200 Ci/mmol) in the presence of 100nM α-CtxMII to block α6β2* nAChRs. After assay,sections are exposed to Kodak MR film.To evaluate binding, optical density readings are converted fmol/mg tissue using 125Istandards. |
动物实验: |
|
Monkeys:Once stable dyskinesias develops,the effects of ABT-089 and Sofiniclin are determined on LIDs.For these studies,there are two sets of MPTP-lesioned monkeys,Set A (n=17) and Set B (n=16).Set A monkeys have previously been treated with nicotine and/or nAChR drugs,followed by a 10 week ishout period (nAChR drug-primed).Set B monkeys have not received any nAChR drug when ABT-089 treatment is initiated (nAChR drug-naive).Our rationale for the use of these two sets of monkeys is to determine if prior treatment with nAChR drugs altered their ability to decrease LIDs.For both sets,there are 3 experimental groups of monkeys,a vehicle-treated group (n=6),a nAChR drug-treated group (n=5 or 6) and a nicotine-treated group (n=5),as a positive control.The monkeys are assigned to the groups such that there are similar number of males and females,with comparable average LID scores. |
本计算器可帮助您计算出特定溶液中溶质的质量、溶液浓度和体积之间的关系,公式为:
质量 (g) = 浓度 (mol/L) x 体积 (L) x 分子量 (g/mol)
摩尔浓度计算公式
用本工具协助配置特定浓度的溶液,使用的计算公式为:
开始浓度 x 开始体积 = 最终浓度 x 最终体积
稀释公式
稀释公式一般简略地表示为:C1V1 = C2V2 ( 输入 输出 )